NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 17:45
Last Report Issued 11/01/2011 06:35

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 2543SP-POS
Patient ID 2543SP-POS
Chain 11003311
DOB Not Given
Sex Not Given
Workorder 11003311
Received 11/01/2011

Lab ID 11003311-001
Matrix Serum or Plasma
Patient Name 2543SP-POS
Patient ID 2543SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2543SP Lurasidone, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Lurasidone	5.0	ng/mL	2.5	
Synonym(s): Latuda®				
Following single dose administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 54 and 64 ng/mL, respectively. Following steady-state administration of 40 mg and 80 mg, the mean Cmax values in serum were approximately 48 and 79 ng/mL, respectively. Peak serum concentrations and absorption occur in approximately 1 to 3 hours. Steady-state concentrations are reached within 7 days of initiation of therapy. The elimination half-life is approximately 18 hours. The white blood cell (WBC) count should be monitored periodically, because agranulocytosis, leukopenia, and neutropenia have been reported during clinical trials.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.